Omnitrope
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Small for Gestational Age
Conditions
Small for Gestational Age
Trial Timeline
Feb 6, 2008 → Mar 25, 2022
NCT ID
NCT00537914About Omnitrope
Omnitrope is a approved stage product being developed by Sandoz Group for Small for Gestational Age. The current trial status is completed. This product is registered under clinical trial identifier NCT00537914. Target conditions include Small for Gestational Age.
What happened to similar drugs?
20 of 20 similar drugs in Small for Gestational Age were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00537914 | Approved | Completed |
Competing Products
20 competing products in Small for Gestational Age
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 40 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Selpercatinib | Eli Lilly | Pre-clinical | 26 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 40 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 33 |
| Pemetrexed | Eli Lilly | Pre-clinical | 26 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 35 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 29 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 22 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 32 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 37 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 27 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 35 |
| Cetuximab | Eli Lilly | Phase 1 | 29 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 40 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 35 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 36 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 39 |